Pancreatic Cancer Research

ResearcherPeking UniversityActive in the last 2 years

Xiaodong Tian

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-0943-5161; OpenAlex author ID A5051841011, A5122989173, A5130407166. Sources: OpenAlex.

Their work

Papers
36 (first author 4, last author 9)
Trials
0
Grants
0
Labs led
1
Collaborators
53
Papers, trials and grants by year

2014: 1 paper · 2015: none · 2016: 1 paper · 2017: none · 2018: 1 paper · 2019: none · 2020: 1 paper · 2021: 9 papers · 2022: 9 papers · 2023: 4 papers · 2024: 2 papers · 2025: 2 papers · 2026: 6 papers

Papers 36

  1. SGLT2 inhibition induces autophagic flux blockade and sensitizes pancreatic cancer to EGFR-targeted therapy. Last author DOI 10.1007/s13402-026-01256-9↗
  2. A deep learning pathomic signature predicts survival and recurrence in pancreatic ductal adenocarcinoma independent of CA19-9. Co-author DOI 10.1016/j.canlet.2026.218452↗
  3. Tumor infiltrating B cells and tertiary lymphoid structures in pancreatic cancer prognosis and therapy. Last author DOI 10.1016/j.isci.2026.116029↗
  4. Chemotherapy-induced senescence promotes stroma stiffness and antioxidant adaptation to promote chemoresistance in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41467-026-75772-5↗
  5. Complement-secreting CAFs are associated with better prognosis in pancreatic cancer: single-cell multiomics. Co-author DOI 10.1136/gutjnl-2025-335683↗
  6. The Acidic Exosomal miR-1246/WASF3 Axis Regulates Hepatic Stellate Cell Activation and Stiff ECM Remodeling to Promote Pancreatic Ductal Adenocarcinoma Liver M… Co-author DOI 10.7150/ijbs.132772↗
  7. Novel CT radiomics models for the postoperative prediction of early recurrence of resectable pancreatic adenocarcinoma: A single-center retrospective study in … Co-author DOI 10.1002/acm2.70092↗
  8. Prognostic implications and characterization of tumor-associated tertiary lymphoid structures genes in pancreatic cancer. Last author DOI 10.1186/s12967-025-06152-8↗
  9. Hypoxia-induced epigenetic regulation of miR-485-3p promotes stemness and chemoresistance in pancreatic ductal adenocarcinoma via SLC7A11-mediated ferroptosis. Co-author DOI 10.1038/s41420-024-02035-x↗
  10. Stem cell-like circulating tumor cells identified by Pep@MNP and their clinical significance in pancreatic cancer metastasis. Co-author DOI 10.3389/fonc.2024.1327280↗
  11. The benefits of neoadjuvant therapy for patients with resectable pancreatic cancer: an updated systematic review and meta-analysis. Co-author DOI 10.1007/s10238-023-01112-2↗
  12. Single-cell RNA-seq reveals characteristics in tumor microenvironment of PDAC with MSI-H following neoadjuvant chemotherapy with anti-PD-1 therapy. Co-author DOI 10.1016/j.canlet.2023.216421↗
  13. Immune profiling and prognostic model of pancreatic cancer using quantitative pathology and single-cell RNA sequencing. Co-author DOI 10.1186/s12967-023-04051-4↗
  14. [Current status and prospects of neoadjuvant therapy for resectable pancreatic cancer]. Co-author DOI 10.3760/cma.j.cn112139-20230510-00199↗
  15. Single cell RNA-seq reveals the CCL5/SDC1 receptor-ligand interaction between T cells and tumor cells in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2022.215834↗
  16. Development and validation of prognostic and diagnostic model for pancreatic ductal adenocarcinoma based on scRNA-seq and bulk-seq datasets. Last author DOI 10.1093/hmg/ddab343↗
  17. MicroRNAs as potential therapeutic targets for pancreatic cancer. Co-author DOI 10.1097/cm9.0000000000001826↗
  18. Predictive Model of Early Death of Resectable Pancreatic Ductal Adenocarcinoma After Curative Resection: A SEER-Based Study. Last author DOI 10.1177/10732748221084853↗
  19. The management strategy of pancreatic cancer in the era of systemic therapy-"Surgery First" or "Surgery Last"? First author DOI 10.21037/hbsn-22-146↗
  20. The effect of minimally invasive or open radical antegrade modular pancreatosplenectomy on pancreatic cancer: A multicenter randomized clinical trial protocol. Co-author DOI 10.3389/fonc.2022.965508↗
  21. Single Cell RNA-Seq Identifies Immune-Related Prognostic Model and Key Signature-SPP1 in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.3390/genes13101760↗
  22. Crosstalk between Pancreatic Cancer Cells and Cancer-Associated Fibroblasts in the Tumor Microenvironment Mediated by Exosomal MicroRNAs. Last author DOI 10.3390/ijms23179512↗
  23. Hypoxic pancreatic cancer derived exosomal miR-30b-5p promotes tumor angiogenesis by inhibiting GJA1 expression. Last author DOI 10.7150/ijbs.67675↗
  24. Single-cell RNA-seq reveals dynamic change in tumor microenvironment during pancreatic ductal adenocarcinoma malignant progression. Co-author DOI 10.1016/j.ebiom.2021.103315↗
  25. A new nomogram for predicting lymph node positivity in pancreatic cancer. Co-author DOI 10.1016/j.hbpd.2020.12.022↗
  26. Inhibition of bone morphogenetic protein receptor 2 suppresses pancreatic ductal adenocarcinoma growth by regulating GRB2/PI3K/AKT axis. Co-author DOI 10.21037/atm-20-2194↗
  27. Molecular characterization of circulating tumor cells in pancreatic ductal adenocarcinoma: potential diagnostic and prognostic significance in clinical practic… Co-author DOI 10.21037/hbsn-20-383↗
  28. Validation and modification of the AJCC 8th TNM staging system for pancreatic ductal adenocarcinoma in a Chinese cohort: A nationwide pancreas data center anal… Co-author DOI 10.21147/j.issn.1000-9604.2021.04.03↗
  29. The Role of Exosomes in Pancreatic Cancer From Bench to Clinical Application: An Updated Review. Co-author DOI 10.3389/fonc.2021.644358↗
  30. [The comparison of prognosis factors after radical resection for pancreatic ductal adenocarcinoma between China Pancreas Data Center and SEER database]. Co-author DOI 10.3760/cma.j.cn112139-20210507-00202↗
  31. Unfolded protein response activated by endoplasmic reticulum stress in pancreatic cancer: potential therapeutical target. Last author DOI 10.52586/5061↗
  32. Predicting early recurrence for resected pancreatic ductal adenocarcinoma: a multicenter retrospective study in China. Co-author PMID 34249444↗
  33. Spatial heterogeneity in epithelial to mesenchymal transition properties of circulating tumor cells associated with distant recurrence in pancreatic cancer pat… Co-author DOI 10.21037/atm-20-782↗
  34. Long noncoding RNA H19 derived miR-675 regulates cell proliferation by down-regulating E2F-1 in human pancreatic ductal adenocarcinoma. First author DOI 10.7150/jca.21347↗
  35. The long noncoding RNA H19 promotes cell proliferation via E2F-1 in pancreatic ductal adenocarcinoma. First author DOI 10.1080/15384047.2016.1219814↗
  36. BRG1 promotes chemoresistance of pancreatic cancer cells through crosstalking with Akt signalling. First author DOI 10.1016/j.ejca.2014.05.017↗

Closest collaborators

The 25 strongest of 53 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yinmo Yang · 18 shared papers, 2016–2026 · strength 3.31
  2. Yongsu Ma · 16 shared papers, 2014–2026 · strength 3.21
  3. Yinmo Yang · 12 shared papers, 2014–2026 · strength 2.25
  4. Kai Chen · 11 shared papers, 2021–2026 · strength 2.13
  5. Yinmo Yang · 5 shared papers, 2021–2026 · strength 1.19
  6. Weikang Liu · 6 shared papers, 2021–2024 · strength 0.95
  7. Enkui Zhang · 3 shared papers, 2025–2026 · strength 0.79
  8. Xiangyu Chu · 3 shared papers, 2022–2024 · strength 0.65
  9. Feng Wang · 5 shared papers, 2016–2022 · strength 0.56
  10. Long Di · 3 shared papers, 2022–2023 · strength 0.55
  11. Di Long · 3 shared papers, 2021–2022 · strength 0.54
  12. Yiran Chen · 3 shared papers, 2021–2025 · strength 0.53
  13. Xinxin Liu · 2 shared papers, 2024–2026 · strength 0.46
  14. Hao Hu · 3 shared papers, 2021 · strength 0.44
  15. Zhengkui Zhang · 4 shared papers, 2016–2021 · strength 0.44
  16. Huahu Guo · 3 shared papers, 2018–2021 · strength 0.37
  17. Marko Kornmann · 4 shared papers, 2014–2021 · strength 0.36
  18. Zichen Pan · 1 shared paper, 2026 · strength 0.33
  19. Yuxin Wang · 1 shared paper, 2026 · strength 0.30
  20. Xiangyu Chu · 1 shared paper, 2026 · strength 0.28
  21. Dongqi Li · 1 shared paper, 2026 · strength 0.28
  22. Xiu Rong Dong · 2 shared papers, 2020–2021 · strength 0.27
  23. Xiaohang Zhao · 2 shared papers, 2020–2021 · strength 0.27
  24. Xiaojuan Du · 1 shared paper, 2025 · strength 0.27
  25. Xu Zhang · 1 shared paper, 2023 · strength 0.26

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.